Wall Street Zen Downgrades Niagen Bioscience (NASDAQ:NAGE) to Buy

Wall Street Zen lowered shares of Niagen Bioscience (NASDAQ:NAGE) from a strong-buy rating to a buy rating in a research report released on Saturday morning.

A number of other analysts have also recently weighed in on the company. Roth Capital reaffirmed a “buy” rating and set a $23.00 price objective (up from $10.00) on shares of Niagen Bioscience in a research report on Friday, June 6th. Canaccord Genuity Group raised their price objective on Niagen Bioscience from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, June 10th.

Niagen Bioscience Stock Up 3.7%

Shares of NASDAQ NAGE opened at $14.14 on Friday. The stock has a market cap of $1.11 billion, a PE ratio of 83.18 and a beta of 2.08. Niagen Bioscience has a 52-week low of $2.31 and a 52-week high of $14.49. The business has a 50-day moving average price of $9.42 and a 200 day moving average price of $7.17.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.